BC Innovations | Jan 7, 2016
Distillery Therapeutics

Therapeutics: Presenilin 1 (PSEN1; PS1)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and rat studies suggest spirocyclic sulfone-based inhibitors of PSEN1-containing γ-secretase could help treat AD without the side effects of inhibiting γ-secretase containing PSEN1 and PSEN2 . Chemical synthesis of...
BC Week In Review | Nov 25, 2013
Clinical News

Warfarin: Phase III data

The double-blind, U.S. Phase III COAG trial in 1,015 patients initiating warfarin therapy with a target INR of 2-3 showed that an algorithm combining a patient's genetic data with clinical variables to determine daily warfarin...
BC Extra | Nov 20, 2013
Top Story

FDA approves first next-gen sequencer

FDA approved the MiSeqDx genome sequencing system from Illumina Inc. (NASDAQ:ILMN) -- the first high-throughput, next-generation genomic sequencer to be approved by the agency. The whole genome benchtop sequencer, which has been available for research-use...
BC Week In Review | Oct 1, 2012
Clinical News

Stivarga regorafenib regulatory update

FDA approved Stivarga regorafenib from Bayer to treat previously treated metastatic colorectal cancer (mCRC) a month ahead of the product's Oct. 27 PDUFA date. Onyx has co-promotion rights in the U.S. to the dual acting...
BC Extra | Sep 28, 2012
Top Story

FDA approves Bayer's regorafenib

FDA approved Stivarga regorafenib from Bayer AG (Xetra:BAYN) to treat previously treated metastatic colorectal cancer (mCRC) a month ahead of the product's Oct. 27 PDUFA date. Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) has co-promotion rights in the...
BC Week In Review | Jul 2, 2012
Clinical News

INFINITI CYP2C19 Assay regulatory update

AutoGenomics Inc. , Carlsbad, Calif.   Product: INFINITI CYP2C19 Assay ; INFINITI Warfarin Assay   Business: Diagnostic   Health Canada approved AutoGenomics' INFINITI Pharmacogenomic (PGx) testing system along with 2 related drug metabolism test kits: INFINITI...
BioCentury | Jun 11, 2012
Emerging Company Profile

Armetheon: Stopping the bleeding

Former ARYx Therapeutics Inc. President Peter Milner co-founded Armetheon Inc. to take a second shot at developing tecarfarin three years after the ARYx anticoagulant failed a Phase II/III trial to prevent blood clots. This time...
BC Week In Review | Apr 25, 2011
Clinical News

Verigene Warfarin Metabolism Nucleic Acid Test regulatory update

Nanosphere received CE Mark approval in the EU for its Verigene Warfarin Metabolism Nucleic Acid Test as an aid in identifying patients at risk for increased warfarin sensitivity. The in vitro diagnostic, which runs on...
BC Extra | Mar 25, 2011
Financial News

AssureRx raises $11 million in series B

AssureRx Health Inc. (Mason, Ohio) raised $11 million in a series B round co-led by Claremont Creek Ventures and Sequoia Capital. New investor Allos Ventures joined existing investors Cincinnati Children's Hospital; Mayo Clinic; and CincyTech...
BC Week In Review | Mar 14, 2011
Clinical News

Warfarin GenoStat Test update

Iverson Genetic began the double-blind, U.S. WARFARIN trial to evaluate the use of its Warfarin GenoSTAT Test to determine warfarin dosing in 4,300 patients. CMS authorized the trial to gather data for future reimbursement considerations....
Items per page:
1 - 10 of 34